• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Therapeutic Vaccine Shows Potential in Fighting Cervical Cancer

Article

In a small, preliminary study, an experimental vaccine provoked a strong immune response against precancerous cells in women treated for cervical lesions that can progress to cancer.

Most cases of cervical cancer are caused by infection with two types of human papillomavirus, or HPV. Some women who have precancerous cervical lesions associated with the Type 16 and Type 18 strains of HPV are able to fight them off without medical intervention. They do so by producing high levels of immune cells called killer T-cells.

Read the full story: http://nyti.ms/SQVgeX

Source: The New York Times

Related Videos
Eric Lander, MD
Eric Lander, MD
David Awad, PharmD, BCOP
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.